Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American depositary share (ADS), which beat the Zacks ...

Total Q1 sales £7.5 billion +2% AER; +4% CERSpecialty Medicines sales £2.9 billion (+17%); Respiratory, Immunology and Inflammation £0.8 billion (+28%); Oncology £0.4 billion (+53%); HIV sales £1.7 ...